基本信息
浏览量:1
职业迁徙
个人简介
His current research focuses on translating basic research findings to the clinic and incorporating multi-modality tools to identify novel druggable targets for cancer treatment. In their quest to characterize cellular pathways that are essential for the oncogenic state, his laboratory has focused on helicases, which are dysregulated in many cancer types. One of the helicase genes they are working on is referred to as DDX3, which is overexpressed in many cancer types and has been associated with lower survival. To target DDX3, his team has synthesized a DDX3 inhibitor, RK‐33, which can potentially be used in cancer treatment. Binding of RK‐33 to DDX3 impedes the function of DDX3, resulting in activation of cell death pathways, inhibition of the Wnt‐signaling pathway, and abrogation of non‐homologous end‐joining (NHEJ) activity. In combination with radiation, synergistic cell death effects have been observed both in vitro and in multiple preclinical cancer models. The group is continuing development of RK-33 as a potential new drug for cancer treatment. In addition, he has been awarded several patents for his research and inventions related to cancer biology.
研究兴趣
论文共 160 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Matthew E. Randolph,Marwa Afifi,Aparna Gorthi, Rachel Weil,Breelyn A. Wilky,Joshua Weinreb, Paul Ciero,Natalie Ter Hoeve,Paul J. van Diest,Venu Raman,Alexander J. R. Bishop,David M. Loeb
Cancer Letters (2024): 216538
crossref(2023)
H. Zhang,C. C. L. Wong, H. Wei,D. M. Gilkes,P. Korangath, P. Chaturvedi,L. Schito,J. Chen,B. Krishnamachary,P. T. Winnard Jr,V. Raman,L. Zhen,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn